{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"75.4","upperLimit":"91.1","value":"85.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"87"}],"units":"Participants"}],"description":"Cumulative incidence of graft failure (neutrophil) by day 28 was reported. Patients who did not have neutrophil engraftment before death was considered as a competing risk. Failure to engraft was defined as lack of evidence of hematopoietic recovery (ANC \\<500/mm3 and platelet count \\< 20,000/mm3) by day +35, confirmed by a biopsy revealing a marrow cellularity \\< 5%. Graft failure was also defined as initial myeloid engraftment by day +35, documented to be of donor origin, followed by a drop in the ANC to \\< 500/mm3 for more than three days, independent of any myelosuppressive drugs, severe GVHD, CMV, or other infection.","dispersionType":"95% Confidence Interval","groups":[{"description":"Although the protocol initially had different disease intensities, ultimately, moved to one regimen for all patients. Subjects received 30mg/m\\^2 of Fludarabine from Day-7 until Day-3, 140mg/m\\^2 of Melphalan on Day-2, and 1.5mg/kg of Rabbit antithymocyte globulin at Day-7,-5,-3 and -1.\"","id":"OG000","title":"Treatment Group"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Transplant (Day 0) through Day +28","title":"Percentage of Participants With Neutrophil Engraftment","type":"PRIMARY","unitOfMeasure":"percentage of patients"}